Review paper outlines 'triad of vascular ageing' and therapeutic frontiers in atherosclerosis

A newly published review paper delineates cellular senescence, inflammaging, and epigenetic dysregulation as the core 'triad of vascular ageing' driving atherosclerosis, emphasizing a clinical shift toward targeting the arterial biological clock rather than lipids alone.

A review paper published in Mechanisms of Ageing and Development in October 2026 explores the 'geroscience hypothesis' in atherosclerotic cardiovascular disease (ASCVD), stating that intrinsic biological ageing of the vascular wall is a primary driver of atherogenesis acting in synergy with circulating lipids.

The authors delineate a pathogenic triad: cellular senescence (triggering the Senescence-Associated Secretory Phenotype in endothelial and vascular smooth muscle cells), systemic inflammaging (driven by metabolically exhausted macrophages, clonal haematopoiesis of indeterminate potential, and cytotoxic memory T cells), and epigenetic dysregulation.

The paper highlights that metabolic stressors like hyperglycaemia induce long-lasting chromatin alterations, establishing trained immunity and a persistent pro-inflammatory metabolic memory.

The authors evaluate the translational frontier of precision senotherapeutics, contrasting senomorphics (such as repurposed metformin and natural polyphenols) with targeted senolytics.

The review highlights emerging preclinical nanotechnologies, including in vivo CAR-T lipid nanoparticles and responsive peptide nanoassemblies, as strategies to selectively clear senescent cells without systemic toxicity.

Traditional lipid-centric clinical models fail to fully address the residual cardiovascular risk observed in older populations, making the biological aging of the vasculature a critical unaddressed therapeutic target.

Identifying the loss of protective sirtuins and aberrant RNA methylation as drivers of epigenetic dysregulation provides clear molecular targets for developing therapeutic interventions against vascular aging.

The review establishes cellular senescence as a central component of atherosclerosis pathology, reinforcing the therapeutic rationale for developing targeted senolytics and senomorphics.

The therapeutic market for cardiovascular disease may increasingly expand beyond standard lipid-lowering therapies to incorporate senotherapeutics and epigenetic modulators.

Development of advanced delivery platforms, such as lipid nanoparticles and responsive peptide nanoassemblies, is likely to see increased translational interest to enable localized or highly selective senescent cell clearance.

Biotechnology firms focusing on sirtuin pathways or cellular rejuvenation may find additional mechanistic validation for their cardiovascular-related pipelines.

Watch for preclinical translation and safety data evaluating in vivo CAR-T lipid nanoparticles and peptide nanoassemblies in animal models of vascular aging and atherosclerosis.